124 related articles for article (PubMed ID: 36801517)
1. Design, synthesis and evaluation of nitric oxide releasing derivatives of 2,4-diaminopyrimidine as novel FAK inhibitors for intervention of metastatic triple-negative breast cancer.
Zhang J; Xu K; Yang F; Qiu Y; Li J; Li J; Wang W; Tan G; Zou Z; Kang F
Eur J Med Chem; 2023 Mar; 250():115192. PubMed ID: 36801517
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel chloropyramine-cinnamic acid hybrids as potential FAK inhibitors for intervention of metastatic triple-negative breast cancer.
Yang F; Xu K; Zhang S; Zhang J; Qiu Y; Luo J; Tan G; Zou Z; Wang W; Kang F
Bioorg Med Chem; 2022 Jul; 66():116809. PubMed ID: 35569251
[TBL] [Abstract][Full Text] [Related]
3. Ophiopogonin D suppresses TGF-β1-mediated metastatic behavior of MDA-MB-231 breast carcinoma cells via regulating ITGB1/FAK/Src/AKT/β-catenin/MMP-9 signaling axis.
Zhu X; Wang K; Chen Y
Toxicol In Vitro; 2020 Dec; 69():104973. PubMed ID: 32818624
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
5. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
[TBL] [Abstract][Full Text] [Related]
7. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells.
Taliaferro-Smith L; Oberlick E; Liu T; McGlothen T; Alcaide T; Tobin R; Donnelly S; Commander R; Kline E; Nagaraju GP; Havel L; Marcus A; Nahta R; O'Regan R
Oncotarget; 2015 Mar; 6(7):4757-72. PubMed ID: 25749031
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel 2,4-diaminopyrimidine cinnamyl derivatives as inhibitors of FAK with potent anti-gastric cancer activities.
Liu Y; Kong LJ; Li N; Liu YH; Jia MQ; Liu QG; Zhang SY; Song J
Bioorg Chem; 2023 Dec; 141():106895. PubMed ID: 37797456
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
10. A chalcone-syringaldehyde hybrid inhibits triple-negative breast cancer cell proliferation and migration by inhibiting CKAP2-mediated FAK and STAT3 phosphorylation.
Jin XX; Mei YN; Shen Z; Zhu JF; Xing SH; Yang HM; Liang G; Zheng XH
Phytomedicine; 2022 Jul; 101():154087. PubMed ID: 35429924
[TBL] [Abstract][Full Text] [Related]
11. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
[TBL] [Abstract][Full Text] [Related]
12. Ziyuglycoside II suppresses the aggressive phenotype of triple negative breast cancer cells through regulating Src/EGFR-dependent ITGB4/FAK signaling.
Wang K; Zou P; Zhu X; Zhang T
Toxicol In Vitro; 2019 Dec; 61():104653. PubMed ID: 31525383
[TBL] [Abstract][Full Text] [Related]
13. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
14. COL8A1 facilitates the growth of triple-negative breast cancer via FAK/Src activation.
Sato F; Sagara A; Tajima K; Miura S; Inaba K; Ando Y; Oku T; Murakami T; Kato Y; Yumoto T
Breast Cancer Res Treat; 2022 Jul; 194(2):243-256. PubMed ID: 35624176
[TBL] [Abstract][Full Text] [Related]
15. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
[TBL] [Abstract][Full Text] [Related]
16. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
17. Rubioncolin C, a natural naphthohydroquinone dimer isolated from Rubia yunnanensis, inhibits the proliferation and metastasis by inducing ROS-mediated apoptotic and autophagic cell death in triple-negative breast cancer cells.
Li L; Wang J; Feng L; Fan J; Wang J; Tan N; Wang Z
J Ethnopharmacol; 2021 Sep; 277():114184. PubMed ID: 33961996
[TBL] [Abstract][Full Text] [Related]
18. Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3.
Ünal TD; Hamurcu Z; Delibaşı N; Çınar V; Güler A; Gökçe S; Nurdinov N; Ozpolat B
Anticancer Agents Med Chem; 2021; 21(3):355-364. PubMed ID: 32767958
[TBL] [Abstract][Full Text] [Related]
19. Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT.
Zhu Y; Tao Z; Chen Y; Lin S; Zhu M; Ji W; Liu X; Li T; Hu X
Breast Cancer Res Treat; 2022 May; 193(1):65-81. PubMed ID: 35254603
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
